Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234123 | 0.89 | NPC1 (0.42) | GRM2GRM3NPC1SMN1; SMN2RAB9A | |
| SCHEMBL1234779 | 0.84 | SMN1; SMN2 (0.49) | NPC1SMN1; SMN2RAB9ACHRM2CHRM1 | |
| SCHEMBL33377212 | 0.83 | NPC1 (0.44) | GRM2GRM3NPC1SMN1; SMN2RAB9A | |
| SCHEMBL1234277 | 0.77 | GAA (0.40) | CHRM2CHRM1CHRM3MAPTKIF11 | |
| SCHEMBL1234777 | 0.76 | SMN1; SMN2 (0.43) | NPC1SMN1; SMN2RAB9ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7269456 | 0.76 | GAA (0.40) | CHRM2CHRM1CHRM3MAPTKIF11 | |
| Hydrochloric Acid SCHEMBL7269422 | 0.75 | SCN5A (0.41) | CHRM2CHRM1CHRM3 | |
| SCHEMBL28856676 | 0.74 | KIF11 (0.37) | NPC1SMN1; SMN2RAB9ACHRM2CHRM1 | |
| SCHEMBL1234252 | 0.73 | ALDH1A1 (0.44) | NPC1SMN1; SMN2RAB9ACHRM2CHRM1 | |
| SCHEMBL28856677 | 0.72 | KIF11 (0.35) | NPC1SMN1; SMN2RAB9ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893087-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-22 | — | — | US | claimed |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | PRAT QUINONES MARIA | 2010-09-16 | — | — | US | claimed |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-06-07 | — | — | US | claimed |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-05-10 | — | — | US | claimed |
| US-7122558-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-10-17 | — | — | US | claimed |
| EP-1353919-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2006-07-26 | — | — | EP | claimed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | claimed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | claimed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | claimed |
| US-7893087-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-22 | — | — | US | disclosed |
| US-7879874-B2 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL, S.A. (ES) | 2011-02-01 | — | — | US | disclosed |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | PRAT QUINONES MARIA | 2010-09-16 | — | — | US | disclosed |
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-06-07 | — | — | US | disclosed |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2007-05-10 | — | — | US | disclosed |
| US-7122558-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL PRODESFARMA AG (CH) | 2006-10-17 | — | — | US | disclosed |
| EP-1353919-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | disclosed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129398-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR2C2, NR1I3 | GRM2 259/4885GRM3 82/4885NPC1 755/4885 |
| US-20100234332-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR0B1, NR4A1, NR0B2 | GRM2 286/4885GRM3 80/4885NPC1 580/4885 |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | CYP11B1, CYP3A7, CBR1 | GRM2 654/4885GRM3 458/4885NPC1 211/4885 |
| US-20070105897-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | NR0B1, NR4A1, NR0B2 | GRM2 346/4885GRM3 95/4885NPC1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.